Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Egypt / NCT07661134
Starting soon Not applicable

Effect of Low Energy Extracorporeal Shockwave on Patients With Bell's Palsy

NCT07661134 · tracked via the Priya Life Science Egypt tracker
Sponsor
Cairo University
Phase
Not applicable
Started
2026-06-25
Last updated
2026-06-22

Condition(s) studied

Bell Palsy

Investigational drug(s) / intervention(s)

Low energy extracorporeal shockwave therapySelective physical therapy program

Low energy extracorporeal shockwave therapy: Participants allocated to the experimental group will receive low-energy extracorporeal shockwave therapy (LE-ESWT) using a shockwave device set at a frequency of 10 Hz, energy intensity of 2.5, and a total dose of 2500 shockwaves per session. The treatment will be delivered to two sites along the facial nerve pathway, including the stylomastoid foramen (500 shockwaves) and a point located 1 cm anterior to the ear (2000 shockwaves). Each session will be administered for approximately 15 minutes throughout the intervention period.

Selective physical therapy program: Participants will receive a standardized physical therapy program including neuromuscular reeducation and massage therapy. Facial exercises will be performed in front of a mirror to improve symmetry and facial muscle control, with therapist assistance provided as needed. Massage therapy will be applied to the neck, scalp, and facial regions. Each treatment session will last approximately 30 minutes.

Study summary

This study aims to investigate the effect of low energy extracorporeal shock wave therapy on patients with Bell's palsy.

Eligibility

Sex
ALL
Min age
45 Years
Max age
55 Years
Healthy volunteers
No
Inclusion Criteria: * Patients with unilateral Bell's palsy (only lower motor neuron lesion). * Patient with idiopathic or viral infection, Bell's palsy. * The age ranged from 45 to 55 years old. * Both males and females are included. * Body mass index (18.5-29.9kg/m2). * It includes the patient in the chronic stage. * All patients are assessed by NCS and other functional scales. * All patients will be referred by neurological consultants. * All patients have controlled diabetes mellitus and are medically stable. Exclusion Criteria: * Patients with a history of facial paralysis post-stroke. * Patients with unstable medical conditions. * Patients with psychiatric disorders. * Patients with other neurological diseases. * Patients with other causes for Bell's palsy. * Patients with diabetic diseases.

Primary outcome measure(s)

  • CMAP Amplitude Asymmetry Percentage — 6 weeks
    Facial nerve function will be assessed using nerve conduction studies (NCS). Compound muscle action potential (CMAP) amplitudes will be recorded bilaterally by stimulating the facial nerve anterior to the mastoid process and recording responses from the nasalis muscle. The percentage of CMAP amplitude asymmetry between the affected and unaffected sides will be calculated as \[(CMAP amplitude affected side - CMAP amplitude unaffected side)/CMAP amplitude unaffected side\] × 100. Lower asymmetry values will indicate improved facial nerve conduction and recovery. Assessments will be performed at baseline and after completion of the treatment program.

Trial sites (1)

FacilityCityRegionStatus
Faculty of Physical Therapy, Cairo University Giza Egypt

More Cairo University trials in Egypt

The Link Between Periodontitis, Smoking and Oral Cancer Starting soon
Treating Intrabony Defect With MINST VS MINST Extended PRF Recruiting
Respiratory Exercises Versus Deep Neck Flexor Training in Chronic Mechanical Neck Pain Recruiting
Integrating Aerobic, Respiratory, and Cognitive Training in Acute Heart Failure Starting soon
Preparation Time Of Bioflx Crowns Compared To Zirconia Crowns On Primary Molars Starting soon

Other trials for the same condition

Efficacy of Prednisolone Versus Cerebrolysin in the Treatment of Bell's Palsy Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07661134 on ClinicalTrials.gov ↗ ← All trials in Egypt